N-acetylcysteine for Idiopathic Pulmonary Fibrosis: A Systematic Review / 中国药房
China Pharmacy
;
(12): 3820-3823, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-661081
ABSTRACT
OBJECTIVE:
To review therapeutic efficacy of N-acetylcysteine (NAC) for idiopathic pulmonary fibrosis (IPF),and to provide evidence-based reference.METHODS:
Retrieved from Central database,PubMed,EMBase,CBM,CJFD,Wanfang database and VIP,randomized controlled trials or semi-randomized controlled trials about NAC (unlimited single drug or combination) vs.placebo/blank control in the treatment of IPF were collected.Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane collaboration's bias risk assessment tool(2014 edition).RESULTS:
A total of 10 studies were included(2 RCT,8 qRCT),involving 742 patients.Results of Meta-analysis showed that compared to placebo/blank control,NAC couldn't reduce the mortality of IPF patients [OR=1.14,95% CI(0.50,2.62),P=0.76],but could significantly improve subjective symptom remission rate[OR=3.17,95% CI (1.98,5.07),P<0.001] and dyspnea score [SMD =-2.54,95 % CI (-5.02,-0.06),P=0.04].CONCLUSIONS:
For IPF,NAC can't decrease the mortality of patients,but can relieve main symptoms and dyspnea.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Ensaio Clínico Controlado
/
Fatores de risco
/
Revisões Sistemáticas Avaliadas
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS